Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CASP1 | P29466 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901946 | 0.86 | TSHR (0.41) | THRBMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL24034328 | 0.84 | THRB (0.43) | THRBMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL23901923 | 0.84 | KMT2A (0.32) | THRBMAPTMEN1KMT2ARXFP1 | |
| SCHEMBL22302407 | 0.81 | THRB (0.38) | THRBMEN1KMT2ARXFP1ALDH1A1 | |
| SCHEMBL23902147 | 0.78 | CYP3A4 (0.43) | THRBALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL23901980 | 0.73 | ACACB (0.32) | — | |
| SCHEMBL24151881 | 0.73 | CYP3A4 (0.42) | THRBALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL24152572 | 0.72 | CYP3A4 (0.40) | THRBALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL24151046 | 0.72 | CYP3A4 (0.40) | THRBALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL21856277 | 0.72 | CYP3A4 (0.39) | THRBALDH1A1TSHRCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4129987-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| WO-2021197452-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | 上海翰森生物医药科技有限公司 | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | PTPN11, PTPN1, PTPN7 | THRB 3360/4885MAPT 3446/4885SMN1; SMN2 2016/4885 |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | PTPN22, PTPN2, PTPN5 | THRB 3525/4885MAPT 975/4885SMN1; SMN2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.